Assertio Holdings, Inc. (ASRT)
USD 0.57
(-3.35%)
USD 0.57
(-3.35%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 38.51 Million USD | -42.0% |
| 2022 | 66.4 Million USD | 8.29% |
| 2021 | 61.31 Million USD | -15.02% |
| 2020 | 72.16 Million USD | -73.4% |
| 2019 | 271.25 Million USD | -52.08% |
| 2018 | 566.1 Million USD | -9.67% |
| 2017 | 626.73 Million USD | -12.81% |
| 2016 | 718.77 Million USD | -10.88% |
| 2015 | 806.5 Million USD | 250.82% |
| 2014 | 229.89 Million USD | 0.0% |
| 2013 | - USD | 0.0% |
| 2012 | - USD | 0.0% |
| 2011 | - USD | 0.0% |
| 2010 | - USD | -100.0% |
| 2009 | 2.17 Million USD | -62.42% |
| 2008 | 5.77 Million USD | 0.0% |
| 2007 | - USD | 0.0% |
| 2006 | - USD | 0.0% |
| 2005 | - USD | -100.0% |
| 2004 | 10.28 Million USD | 8.24% |
| 2003 | 9.49 Million USD | 2365.56% |
| 2002 | 385.22 Thousand USD | -93.08% |
| 2001 | 5.56 Million USD | 214.68% |
| 2000 | 1.76 Million USD | 330.83% |
| 1999 | 410.6 Thousand USD | -17.88% |
| 1998 | 500 Thousand USD | 0.0% |
| 1997 | - USD | 0.0% |
| 1996 | - USD | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q2 | 38.72 Million USD | 0.28% |
| 2024 Q1 | 38.62 Million USD | 0.28% |
| 2023 Q4 | 38.51 Million USD | -0.91% |
| 2023 Q2 | 38.25 Million USD | 0.26% |
| 2023 FY | 38.51 Million USD | -42.0% |
| 2023 Q3 | 38.86 Million USD | 1.61% |
| 2023 Q1 | 38.15 Million USD | -42.55% |
| 2022 Q2 | 49.5 Million USD | -19.18% |
| 2022 Q4 | 66.4 Million USD | 0.64% |
| 2022 FY | 66.4 Million USD | 8.29% |
| 2022 Q3 | 65.98 Million USD | 33.3% |
| 2022 Q1 | 61.25 Million USD | -0.11% |
| 2021 Q3 | 66.41 Million USD | -0.51% |
| 2021 FY | 61.31 Million USD | -15.02% |
| 2021 Q4 | 61.31 Million USD | -7.67% |
| 2021 Q1 | 71.83 Million USD | -0.45% |
| 2021 Q2 | 66.75 Million USD | -7.08% |
| 2020 Q4 | 72.16 Million USD | -6.57% |
| 2020 Q1 | - USD | -100.0% |
| 2020 Q2 | 91.83 Million USD | 0.0% |
| 2020 Q3 | 77.23 Million USD | -15.9% |
| 2020 FY | 72.16 Million USD | -73.4% |
| 2019 Q1 | 429.02 Million USD | -24.22% |
| 2019 Q2 | 415.07 Million USD | -3.25% |
| 2019 Q4 | 271.25 Million USD | -5.02% |
| 2019 Q3 | 285.58 Million USD | -31.2% |
| 2019 FY | 271.25 Million USD | -52.08% |
| 2018 Q1 | 524.64 Million USD | -16.29% |
| 2018 FY | 566.1 Million USD | -9.67% |
| 2018 Q4 | 566.1 Million USD | 22.93% |
| 2018 Q3 | 460.52 Million USD | -20.6% |
| 2018 Q2 | 580.03 Million USD | 10.56% |
| 2017 Q2 | 572.05 Million USD | -8.24% |
| 2017 Q4 | 626.73 Million USD | 8.64% |
| 2017 FY | 626.73 Million USD | -12.81% |
| 2017 Q1 | 623.42 Million USD | -13.27% |
| 2017 Q3 | 576.88 Million USD | 0.85% |
| 2016 Q4 | 718.77 Million USD | 0.64% |
| 2016 Q3 | 714.18 Million USD | 0.63% |
| 2016 FY | 718.77 Million USD | -10.88% |
| 2016 Q1 | 704.56 Million USD | -12.64% |
| 2016 Q2 | 709.72 Million USD | 0.73% |
| 2015 Q4 | 806.5 Million USD | 0.49% |
| 2015 Q3 | 802.6 Million USD | 0.47% |
| 2015 Q2 | 798.83 Million USD | 242.76% |
| 2015 Q1 | 233.05 Million USD | 1.38% |
| 2015 FY | 806.5 Million USD | 250.82% |
| 2014 Q1 | - USD | 0.0% |
| 2014 Q2 | - USD | 0.0% |
| 2014 Q4 | 229.89 Million USD | 1.38% |
| 2014 FY | 229.89 Million USD | 0.0% |
| 2014 Q3 | 226.77 Million USD | 0.0% |
| 2013 Q1 | - USD | 0.0% |
| 2013 Q2 | - USD | 0.0% |
| 2013 Q3 | - USD | 0.0% |
| 2013 Q4 | - USD | 0.0% |
| 2013 FY | - USD | 0.0% |
| 2012 Q2 | - USD | 0.0% |
| 2012 FY | - USD | 0.0% |
| 2012 Q1 | - USD | 0.0% |
| 2012 Q4 | - USD | 0.0% |
| 2012 Q3 | - USD | 0.0% |
| 2011 Q2 | - USD | 0.0% |
| 2011 FY | - USD | 0.0% |
| 2011 Q3 | - USD | 0.0% |
| 2011 Q1 | - USD | 0.0% |
| 2011 Q4 | - USD | 0.0% |
| 2010 FY | - USD | -100.0% |
| 2010 Q4 | - USD | 0.0% |
| 2010 Q2 | 121 Thousand USD | -89.57% |
| 2010 Q3 | - USD | -100.0% |
| 2010 Q1 | 1.16 Million USD | -46.54% |
| 2009 Q4 | 2.17 Million USD | -31.09% |
| 2009 Q1 | 5.02 Million USD | -13.07% |
| 2009 Q3 | 3.14 Million USD | -23.18% |
| 2009 Q2 | 4.09 Million USD | -18.35% |
| 2009 FY | 2.17 Million USD | -62.42% |
| 2008 Q4 | 5.77 Million USD | -11.14% |
| 2008 Q1 | - USD | 0.0% |
| 2008 FY | 5.77 Million USD | 0.0% |
| 2008 Q2 | 2.92 Million USD | 0.0% |
| 2008 Q3 | 6.49 Million USD | 122.19% |
| 2007 Q4 | - USD | 0.0% |
| 2007 FY | - USD | 0.0% |
| 2007 Q2 | - USD | 0.0% |
| 2007 Q3 | - USD | 0.0% |
| 2007 Q1 | - USD | 0.0% |
| 2006 Q4 | - USD | 0.0% |
| 2006 Q3 | - USD | 0.0% |
| 2006 FY | - USD | 0.0% |
| 2006 Q1 | - USD | 0.0% |
| 2006 Q2 | - USD | 0.0% |
| 2005 Q4 | - USD | 0.0% |
| 2005 Q2 | - USD | 0.0% |
| 2005 Q1 | - USD | -100.0% |
| 2005 FY | - USD | -100.0% |
| 2005 Q3 | - USD | 0.0% |
| 2004 FY | 10.28 Million USD | 8.24% |
| 2004 Q2 | 9.83 Million USD | 2.06% |
| 2004 Q4 | 10.28 Million USD | 2.26% |
| 2004 Q3 | 10.05 Million USD | 2.17% |
| 2004 Q1 | 9.64 Million USD | 1.51% |
| 2003 Q4 | 9.49 Million USD | 1.57% |
| 2003 Q3 | 9.35 Million USD | 1.54% |
| 2003 Q2 | 9.2 Million USD | 1.39% |
| 2003 Q1 | 9.08 Million USD | 2257.91% |
| 2003 FY | 9.49 Million USD | 2365.56% |
| 2002 Q2 | 6.47 Million USD | 0.6% |
| 2002 Q3 | 6.5 Million USD | 0.44% |
| 2002 Q4 | 385.22 Thousand USD | -94.07% |
| 2002 FY | 385.22 Thousand USD | -93.08% |
| 2002 Q1 | 6.43 Million USD | 15.56% |
| 2001 Q2 | 3.38 Million USD | 14.57% |
| 2001 Q3 | 4.61 Million USD | 36.49% |
| 2001 Q4 | 5.56 Million USD | 20.57% |
| 2001 FY | 5.56 Million USD | 214.68% |
| 2001 Q1 | 2.95 Million USD | 66.89% |
| 2000 Q2 | 325.29 Thousand USD | -11.75% |
| 2000 Q3 | 1.27 Million USD | 291.74% |
| 2000 Q4 | 1.76 Million USD | 38.82% |
| 2000 FY | 1.76 Million USD | 330.83% |
| 2000 Q1 | 368.6 Thousand USD | -10.23% |
| 1999 Q1 | 400 Thousand USD | -20.0% |
| 1999 Q3 | 500 Thousand USD | 0.0% |
| 1999 Q4 | 410.6 Thousand USD | -17.88% |
| 1999 FY | 410.6 Thousand USD | -17.88% |
| 1999 Q2 | 500 Thousand USD | 25.0% |
| 1998 FY | 500 Thousand USD | 0.0% |
| 1998 Q1 | 100 Thousand USD | 0.0% |
| 1998 Q2 | 100 Thousand USD | 0.0% |
| 1998 Q4 | 500 Thousand USD | 400.0% |
| 1998 Q3 | 100 Thousand USD | 0.0% |
| 1997 Q3 | - USD | 0.0% |
| 1997 Q4 | - USD | 0.0% |
| 1997 FY | - USD | 0.0% |
| 1996 FY | - USD | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| ANI Pharmaceuticals, Inc. | 309.66 Million USD | 87.563% |
| Aquestive Therapeutics, Inc. | 91.07 Million USD | 57.712% |
| Collegium Pharmaceutical, Inc. | 489.96 Million USD | 92.139% |
| Dynavax Technologies Corporation | 252.41 Million USD | 84.742% |
| Esperion Therapeutics, Inc. | 501.54 Million USD | 92.321% |
| Cosmos Health Inc. | 3.03 Million USD | -1168.852% |
| Pacira BioSciences, Inc. | 513.79 Million USD | 92.504% |
| PainReform Ltd. | 30 Thousand USD | -128280.0% |
| Sunshine Biopharma, Inc. | 539.03 Thousand USD | -7044.991% |
| Sunshine Biopharma, Inc. | 539.03 Thousand USD | -7044.991% |
| SCYNEXIS, Inc. | 12.15 Million USD | -216.753% |
| Safety Shot Inc | 304.9 Thousand USD | -12531.393% |
| China SXT Pharmaceuticals, Inc. | 117.12 Thousand USD | -32781.695% |
| Alpha Teknova, Inc. | 13.25 Million USD | -190.65% |
| Embecta Corp. | 1.62 Billion USD | 97.63% |
| Bright Green Corporation | 201.78 Thousand USD | -18986.841% |
| Intra-Cellular Therapies, Inc. | 13.32 Million USD | -189.014% |
| Journey Medical Corporation | 14.62 Million USD | -163.398% |
| Procaps Group, S.A. | 28.41 Million USD | -35.565% |
| Theratechnologies Inc. | 51.26 Million USD | 24.867% |
| Harrow Health, Inc. | 183.17 Million USD | 78.974% |
| Sonoma Pharmaceuticals, Inc. | 87 Thousand USD | -44168.966% |
| Biofrontera Inc. | 804 Thousand USD | -4690.299% |
| DURECT Corporation | 2.7 Million USD | -1325.389% |
| Supernus Pharmaceuticals, Inc. | 33.19 Million USD | -16.02% |
| Cronos Group Inc. | 1.55 Million USD | -2370.43% |
| OptiNose, Inc. | 611 Thousand USD | -6203.437% |
| Ironwood Pharmaceuticals, Inc. | 498.3 Million USD | 92.271% |
| Kala Pharmaceuticals, Inc. | 34.19 Million USD | -12.647% |
| RedHill Biopharma Ltd. | 455 Thousand USD | -8364.615% |
| Organogenesis Holdings Inc. | 60.74 Million USD | 36.597% |
| Guardion Health Sciences, Inc. | - USD | -Infinity% |
| Cumberland Pharmaceuticals Inc. | 12.78 Million USD | -201.264% |
| Radius Health, Inc. | 339.66 Million USD | 88.661% |
| Universe Pharmaceuticals INC | - USD | -Infinity% |
| ProPhase Labs, Inc. | 10.25 Million USD | -275.453% |
| Phibro Animal Health Corporation | 458.28 Million USD | 91.596% |
| Procaps Group S.A. | 28.41 Million USD | -35.565% |
| Alvotech | 1.02 Billion USD | 96.253% |
| TherapeuticsMD, Inc. | 6.53 Million USD | -489.62% |
| Viatris Inc. | 16.18 Billion USD | 99.762% |
| Rockwell Medical, Inc. | 8.29 Million USD | -364.416% |
| Aytu BioPharma, Inc. | 10.87 Million USD | -254.087% |
| SIGA Technologies, Inc. | 335.99 Thousand USD | -11362.807% |
| Tilray Brands, Inc. | 287.93 Million USD | 86.624% |
| Lifecore Biomedical, Inc. | 120.51 Million USD | 68.041% |
| Shineco, Inc. | 10.01 Million USD | -284.474% |
| PetIQ, Inc. | 437.82 Million USD | 91.203% |
| Regencell Bioscience Holdings Limited | - USD | -Infinity% |
| Incannex Healthcare Limited | 210 Thousand USD | -18240.0% |
| Neurocrine Biosciences, Inc. | 258.3 Million USD | 85.089% |
| Alimera Sciences, Inc. | 64.48 Million USD | 40.278% |
| Silver Spike Investment Corp. | - USD | -Infinity% |
| Shuttle Pharmaceuticals Holdings, Inc. | 135.08 Thousand USD | -28410.093% |
| Petros Pharmaceuticals, Inc. | 6.85 Million USD | -461.644% |
| Clever Leaves Holdings Inc. | 720 Thousand USD | -5249.167% |
| Cyclo Therapeutics, Inc. | 22.48 Thousand USD | -171195.143% |
| Avadel Pharmaceuticals plc | 32.75 Million USD | -17.564% |
| Hempacco Co., Inc. | 5.93 Million USD | -549.368% |
| Talphera, Inc. | - USD | -Infinity% |
| Alvotech | 1.02 Billion USD | 96.253% |
| Eagle Pharmaceuticals, Inc. | 56.21 Million USD | 31.489% |
| Lantheus Holdings, Inc. | 616.12 Million USD | 93.749% |
| Currenc Group, Inc. | 2.5 Million USD | -1436.274% |
| Kamada Ltd. | 7.43 Million USD | -417.8% |
| Indivior PLC | 235.66 Million USD | 83.657% |
| Evoke Pharma, Inc. | 5 Million USD | -670.28% |
| Flora Growth Corp. | 942 Thousand USD | -3988.535% |
| Cyclo Therapeutics, Inc. | 22.48 Thousand USD | -171195.143% |
| Evolus, Inc. | 120.35 Million USD | 68.001% |
| HUTCHMED (China) Limited | 48.18 Million USD | 20.077% |
| Amphastar Pharmaceuticals, Inc. | 589.19 Million USD | 93.463% |
| Akanda Corp. | 2.49 Million USD | -1442.315% |